Guaranteed antibody humanization
Antibody humanization is a rapid and reliable developmental process which offers:
- Short clinical developmental times
- High regulatory approval rates
- Better management of risk
Our Biotherapeutics group (part of MRCTs Centre for Therapeutics Discovery) has substantial antibody engineering know-how. To take advantage of our expertise please contact Dr John Kelly or complete this form.
Humanized antibodies to novel targets
We have been humanizing antibodies for the better part of quarter of a century and our expertise has been used by the world’s leading pharmaceutical and biotech companies.
The technique we use (CDR grafting) was developed at the MRC giving our scientists unrivalled knowledge about this specialised discipline. We also offer other engineering services such as affinity maturation and biophysical characterisation.
Our experts have humanized more than 50 antibodies, which include two marketed products: Tysabri and Actemra. A further six are in clinical trials (including Vedolizumab), with two more in preclinical studies.
No upfront fees
We do not charge an upfront fee to companies for our humanization service, with our return coming from success milestone payments and a small product royalty.
Universities and charities
We offer a shared-risk collaboratation model to institutions wishing to humanize their antibody portfolio.
Our humanization services
- You only pay for success
- Advising on candidate selection
- Humanizing your candidate monoclonals and delivering a regulatory compliant package
Enquire about our humanzing services
To take advantage of our antibody humanization expertise please contact Dr John Kelly
Humanized antibody design, construction and testing
Humanization is a rapid process, only taking one week to generate several optimised human antibody designs. in full it takes 12-15 weeks to design the variants, build the constructs and screen for the optimum candidate antibody. Our process ensures that we can monitor, asses and maintain our progress at all times.
- In-silico modelling and humanization design
- Screening and selection of candidates